MENORA MIVTACHIM HOLDINGS LTD.MENORA MIVTACHIM HOLDINGS LTD.

Institutional investor · Portfolio as of Q4 2023

SEC EDGAR SourceSEC Filings

Top Holdings97 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

MICROSOFT CORP

2.8M$1.1B9.0%$221.46+67.31%
20 qtrssince 2019-Q1
Decreased
0

APPLE INC

4.2M$801.1M6.7%$125.64+51.40%
20 qtrssince 2019-Q1
Increased
63

ALPHABET INC-CL A

5M$704.6M5.9%$99.76+38.98%
20 qtrssince 2019-Q1
Increased
64

APPLIED MATERIALS INC

3.2M$520.4M4.4%$121.24+31.00%
12 qtrssince 2021-Q1
Increased
60

MASTERCARD INC - A

1M$428.8M3.6%$338.46+24.39%
12 qtrssince 2021-Q1
Decreased
0

META PLATFORMS INC-CLASS A

1.2M$417.3M3.5%$262.53+33.89%
15 qtrssince 2020-Q2
Increased
60

AMAZON.COM INC

2.7M$406.4M3.4%$114.58+32.61%
20 qtrssince 2019-Q1
Increased
63
FLINFLIN
ETF

FRANKLIN TEMPLETON ETF TR

9.5M$333M2.8%$31.51+8.42%
3 qtrssince 2023-Q2
Increased
74

UNITEDHEALTH GROUP INC

632,416$332.9M2.8%$472.35+7.10%
5 qtrssince 2022-Q4
Increased
60
TEVATEVA
ADR

TEVA PHARMACEUTICAL-SP ADR

28.1M$293.7M2.5%$9.33+11.89%
17 qtrssince 2019-Q4
Unchanged
0

ABBOTT LABORATORIES

2.7M$291.9M2.5%$98.12+5.97%
14 qtrssince 2020-Q3
Increased
59

WALMART INC

1.8M$290.6M2.4%$42.80+20.20%
20 qtrssince 2019-Q1
Increased
60

JPMORGAN CHASE & CO

1.6M$265.7M2.2%$142.84+13.39%
2 qtrssince 2023-Q3
Increased
67
EMXCEMXC
ETF

ISHARES MSCI EMR MRK EX CHNA

4.5M$247.8M2.1%$46.31+13.11%
4 qtrssince 2023-Q1
Decreased
0
TSMTSM
ADR

TAIWAN SEMICONDUCTOR SPONSORED ADR /1 ADR REPS 5 ORD SHS/

2.3M$238.5M2.0%$88.42+14.43%
5 qtrssince 2022-Q4
Increased
69

THERMO FISHER SCIENTIFIC INC

423,889$225M1.9%$391.33+34.79%
20 qtrssince 2019-Q1
Unchanged
0

OTIS WORLDWIDE CORP

2.5M$220.2M1.9%$61.04+39.38%
15 qtrssince 2020-Q2
Increased
53

MONDELEZ INTERNATIONAL INC-A

3M$214.4M1.8%$57.90+18.06%
14 qtrssince 2020-Q3
Increased
59

HOME DEPOT INC

603,932$209.3M1.8%$261.43+26.24%
20 qtrssince 2019-Q1
Increased
57
FLKRFLKR
ETF

FRANKLIN TEMPLETON ETF TR

9M$204.5M1.7%$18.50+11.24%
4 qtrssince 2023-Q1
Decreased
0
$11.9B
AUM
97
Positions
Q4 2023
Filing
Rating · 2.0
Quarterly Portfolio Change
-3%Q3'22$5.3B+12%Q4'22$5.9B+63%Q1'23$9.7B+12%Q2'23$10.8B+2%Q3'23$11B+8%Q4'23$11.9B
Activity profile
$ moved · Q4'23
New12%Increased42%Decreased32%Exited14%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.3 years
<1Q4%1-4Q42%1-2Y3%2Y+51%

MENORA MIVTACHIM HOLDINGS LTD. manages $11.9B across 97 positions as of Q4 2023. Top holdings: MSFT (9.0%), AAPL (6.7%), GOOGL (5.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2/5.0.

Q4 2023 Summary

Active quarter - 8 new positions, 6 exits, 27 increased. Top move: FLIN (INCREASED, conviction 74). Portfolio: $11.9B across 97 positions.

Top holdings by portfolio weight

Total AUM$12B
MSFT8.99%
AAPL6.74%
GOOGL5.93%
AMAT4.38%
MA3.61%
META3.51%
AMZN3.42%
FLIN2.80%
UNH2.80%
TEVA2.47%
Other2.46%

Portfolio allocation by GICS sector

Sectors11
Technology31.41%
Unknown12.54%
Healthcare11.68%
Communication Services9.99%
Financial Services9.87%
Consumer Cyclical8.56%
Industrials4.48%
Consumer Defensive4.25%
Basic Materials2.63%
Real Estate2.22%
Other2.39%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Technology, Unknown, Healthcare
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record52
Conviction45
Concentration62
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
6Q
TEVATEVATEVA PHARMACEUTICAL-SP ADR
Q1 2025 Q2 2026+11.5M shares+$724.7M
5Q
KREKRESPDR SERIES TRUST
Q2 2025 Q2 2026+3.3M shares+$248M
4Q
QQQQQQINVESCO QQQ TRUST SERIES 1 CL USD INC
Q3 2025 Q2 2026+10,060 shares+$9.7M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used